Open AccessReal-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma
Author(s) -
Baojiang Liu,
Song Gao,
Xu Zhu,
Jun Guo,
Fuxin Kou,
Shao-Xing Liu,
Xin Zhang,
Xiaodong Wang,
Guang Cao,
Hui Chen,
Peng Liu,
Haifeng Xu,
Qin-Zong Gao,
Renjie Yang
Publication year - 2021
Publication title -
immunotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.127
H-Index - 48
eISSN - 1750-7448
pISSN - 1750-743X
DOI - 10.2217/imt-2021-0192
Subject(s) - medicine , sorafenib , hepatocellular carcinoma , chemotherapy , immunotherapy , oncology , gastroenterology , tyrosine kinase inhibitor , lenvatinib , cancer
Aim: We investigated the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors (TKIs) for advanced hepatocellular carcinoma (HCC). Method: This retrospective study included HCC patients treated with HAIC, TKIs and anti-PD-1 antibodies between May 2019 and November 2020 in our hospital. Primary end points were progression-free survival and safety. Results: Twenty-seven advanced HCC patients were analyzed. The median follow-up was 12.9 months (range: 4.0–24.0 months) and the median progression-free survival was 10.6 months. The objective response rate and disease control rate were 63.0 and 92.6%, respectively. No treatment-related deaths occurred. Conclusion: In patients with advanced HCC, treatment with HAIC, anti-PD-1 antibodies and oral TKIs was effective and safe.